Skip to main content
. 2014 Oct 28;137(12):3284–3299. doi: 10.1093/brain/awu293

Table 1.

Molecular pathology data for patients with PCA and typical Alzheimer’s disease

Diagnosis Amyloid 18 F imaging CSF total tau pg/ml CSF amyoid-β1-42 pg/ml CSF tau:amyloid-β ratio Interpretation
PCA Not available 310 488 0.64
PCA Not available 931 625 1.49 +
PCA positive 1072 126 8.51 ++
PCA Not available 151 147 1.03 +
PCA positive Not available Not available Not available ++
PCA positive 1082 365 2.96 ++
PCA positive Not available Not available Not available ++
tAD Not available 289 280 1.03 +
tAD Not available 757 285 2.66 ++
tAD Not available 940 348 2.70 ++
tAD Not available 952 195 4.88 ++
tAD Not available 977 322 3.03 ++
tAD Not available 625 277 2.26 ++
tAD Not available >1200 313 >3.83 ++
tAD Not available 913 191 4.78 ++
tAD Not available >1200 217 >5.52 ++
tAD Not available 1099 195 5.64 ++
tAD Not available 850 362 2.35 ++

tAD = typical Alzheimer’s disease.

Where results do not support Alzheimer’s disease pathology (−), are borderline consistent with Alzheimer’s disease pathology (+) and are >85% specific for Alzheimer’s disease pathology (++). Amyloid (florbetapir) PET scans were received as part of another investigation.